secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001615219-25-000162
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.01, 3.02, 3.03, 5.03, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius completes acquisition of Decoy Therapeutics, raises ~$6.3M in public offering
--------------------------------------------------------------------------------

- Closed merger with Decoy Therapeutics on Nov 12; issued Series A/B Preferred Stock convertible at 2,800:1 ratio post-anti-dilution adjustment.
- Public offering priced at $1.50/unit (common + Series A/B warrants); net proceeds ~$6.3M, closed Nov 12.
- Frederick Pierce (Decoy CEO) appointed CEO, replacing Mark Rosenblum who remains CFO; Dr. Barbara Hibner as CSO, Peter Marschel as CBO.
- Board change: Pierce appointed Class II director; Bruce McCreedy resigned, not due to any disagreement.
- Warrants: Series A (5-yr term, $1.50 exercise), Series B (1-yr term, $1.50), Pre-funded ($0.0001). Representative warrants also issued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000162/0001615219-25-000162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000162/flks-20251111.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer